CIK 0002040807
MTSR Metsera, Inc.
Insider trading from SEC Form 4. Last filing May 22, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
12
with a Form 4 at this company
Signals
Open-market buys and sells at Metsera, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | ARCH Venture Partners XII, LLC owner buy | $40M 2,222,222 shares | +13% | - | |
| 58Moderate | Paul L Berns director buy | $14M 789,998 shares | +11% | - | |
| 58Moderate | Kristina Burow director, owner buy | $40M 2,222,222 shares | +13% | - |
Transactions
The last 38 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 20, 2025 | Paul L Berns director | AGrant or award Stock Option (Right to Buy)derivative | +24,188 | $0.00 | $0 | 24,188 | May 22, 2025 |
| May 20, 2025 | Christopher Whitten Bernard President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +348,750 | $0.00 | $0 | 348,750 | May 22, 2025 |
| May 20, 2025 | Kristina Burow director | AGrant or award Stock Option (Right to Buy)derivative | +16,125 | $0.00 | $0 | 16,125 | May 22, 2025 |
| May 20, 2025 | Brian Hubbard Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +120,000 | $0.00 | $0 | 120,000 | May 22, 2025 |
| May 20, 2025 | Matthew Lang Chief Legal Officer | AGrant or award Stock Option (Right to Buy)derivative | +46,875 | $0.00 | $0 | 46,875 | May 22, 2025 |
| May 20, 2025 | Clive Meanwell Executive Chairman | AGrant or award Stock Option (Right to Buy)derivative | +32,250 | $0.00 | $0 | 32,250 | May 22, 2025 |
| May 20, 2025 | Steven Marso Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +120,000 | $0.00 | $0 | 120,000 | May 22, 2025 |
| May 20, 2025 | Christopher Visioli Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +150,000 | $0.00 | $0 | 150,000 | May 22, 2025 |
| May 20, 2025 | Joshua Pinto director | AGrant or award Stock Option (Right to Buy)derivative | +16,125 | $0.00 | $0 | 16,125 | May 22, 2025 |
| May 22, 2025 | Joshua Pinto director | GGift Stock Option (Right to Buy)derivative | -148,953 | $0.00 | $0 | 0 | May 22, 2025 |
| May 22, 2025 | Joshua Pinto director | GGift Stock Option (Right to Buy)derivativeindirect: By LLC | +148,953 | $0.00 | $0 | 148,953 | May 22, 2025 |
| Apr 28, 2025 | Jon P Stonehouse director | AGrant or award Stock Option (Right to Buy)derivative | +47,730 | $19.81 | $946k | 47,730 | Apr 30, 2025 |
| Feb 3, 2025 | Fmr LLC owner, other | CConversion Common Stockindirect: F-Prime Capital Partners Life Sciences Fund VIII LP | +1,418,606 | - | - | 1,418,606 | Feb 5, 2025 |
| Feb 3, 2025 | Fmr LLC owner, other | CConversion Common Stockindirect: F-Prime Capital Partners Life Sciences Fund VIII LP | +3,120,934 | - | - | 4,539,540 | Feb 5, 2025 |
| Feb 3, 2025 | Fmr LLC owner, other | CConversion Series Seed Preferred Stockderivativeindirect: F-Prime Capital Partners Life Sciences Fund VIII LP | -1,418,606 | - | - | 0 | Feb 5, 2025 |
| Feb 3, 2025 | Fmr LLC owner, other | CConversion Series A Preferred Stockderivativeindirect: F-Prime Capital Partners Life Sciences Fund VIII LP | -3,120,934 | - | - | 0 | Feb 5, 2025 |
| Feb 3, 2025 | ARCH Venture Partners XII, LLC owner | CConversion Common Stockindirect: See Footnote | +16,006,949 | - | - | 17,070,904 | Feb 3, 2025 |
| Feb 3, 2025 | Paul L Berns director | CConversion Common Stockindirect: See footnote | +7,523,682 | - | - | 7,523,682 | Feb 3, 2025 |
| Feb 3, 2025 | Kristina Burow director, owner | CConversion Common Stockindirect: See footnote | +16,006,949 | - | - | 17,070,904 | Feb 3, 2025 |
| Feb 3, 2025 | ARCH Venture Partners XII, LLC owner | CConversion Common Stockindirect: See Footnote | +7,523,682 | - | - | 7,523,682 | Feb 3, 2025 |
| Feb 3, 2025 | Kristina Burow director, owner | POpen-market purchase Common Stockindirect: See footnote | +1,432,224 | $18.00 | $26M | 18,503,128 | Feb 3, 2025 |
| Feb 3, 2025 | Paul L Berns director | POpen-market purchase Common Stockindirect: See footnote | +789,998 | $18.00 | $14M | 8,313,680 | Feb 3, 2025 |
| Feb 3, 2025 | Kristina Burow director, owner | CConversion Common Stockindirect: See footnote | +7,523,682 | - | - | 7,523,682 | Feb 3, 2025 |
| Feb 3, 2025 | ARCH Venture Partners XII, LLC owner | POpen-market purchase Common Stockindirect: See Footnote | +1,432,224 | $18.00 | $26M | 18,503,128 | Feb 3, 2025 |
| Feb 3, 2025 | Paul L Berns director | CConversion Series A Convertible Preferred Stockderivativeindirect: See footnote | -15,000,000 | - | - | 0 | Feb 3, 2025 |
| Feb 3, 2025 | Kristina Burow director, owner | POpen-market purchase Common Stockindirect: See footnote | +789,998 | $18.00 | $14M | 8,313,680 | Feb 3, 2025 |
| Feb 3, 2025 | ARCH Venture Partners XII, LLC owner | POpen-market purchase Common Stockindirect: See Footnote | +789,998 | $18.00 | $14M | 8,313,680 | Feb 3, 2025 |
| Feb 3, 2025 | Paul L Berns director | CConversion Series B Convertible Preferred Stockderivativeindirect: See footnote | -2,678,571 | - | - | 0 | Feb 3, 2025 |
| Feb 3, 2025 | ARCH Venture Partners XII, LLC owner | CConversion Series Seed Preferred Stockderivativeindirect: See Footnote | -19,933,333 | - | - | 0 | Feb 3, 2025 |
| Feb 3, 2025 | Kristina Burow director, owner | CConversion Series Seed Preferred Stockderivativeindirect: See footnote | -19,933,333 | - | - | 0 | Feb 3, 2025 |
| Feb 3, 2025 | Kristina Burow director, owner | CConversion Series A Convertible Preferred Stockderivativeindirect: See footnote | -15,000,000 | - | - | 0 | Feb 3, 2025 |
| Feb 3, 2025 | ARCH Venture Partners XII, LLC owner | CConversion Series A Convertible Preferred Stockderivativeindirect: See Footnote | -15,000,000 | - | - | 0 | Feb 3, 2025 |
| Feb 3, 2025 | Kristina Burow director, owner | CConversion Series B Convertible Preferred Stockderivativeindirect: See footnote | -2,678,571 | - | - | 0 | Feb 3, 2025 |
| Feb 3, 2025 | ARCH Venture Partners XII, LLC owner | CConversion Series B Convertible Preferred Stockderivativeindirect: See Footnote | -2,678,571 | - | - | 0 | Feb 3, 2025 |
| Feb 3, 2025 | Kristina Burow director, owner | CConversion Series A Convertible Preferred Stockderivativeindirect: See footnote | -15,000,000 | - | - | 0 | Feb 3, 2025 |
| Feb 3, 2025 | ARCH Venture Partners XII, LLC owner | CConversion Series A Convertible Preferred Stockderivativeindirect: See Footnote | -15,000,000 | - | - | 0 | Feb 3, 2025 |
| Feb 3, 2025 | ARCH Venture Partners XII, LLC owner | CConversion Series B Convertible Preferred Stockderivativeindirect: See Footnote | -2,678,571 | - | - | 0 | Feb 3, 2025 |
| Feb 3, 2025 | Kristina Burow director, owner | CConversion Series B Convertible Preferred Stockderivativeindirect: See footnote | -2,678,571 | - | - | 0 | Feb 3, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- ARCH Venture Partners XII, LLCowner
- Paul L Bernsdirector, officer
- Christopher Whitten BernardPresident and CEO
- Kristina Burowdirector, owner
- Fmr LLCowner, other
- Brian HubbardChief Scientific Officer
- Matthew LangChief Legal Officer
- Clive MeanwellExecutive Chairman
- Steven MarsoChief Medical Officer
- Joshua Pintodirector, president, officer
- Jon P Stonehouseceo, president, officer, director
- Christopher VisioliChief Financial Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.